\-\ Texto\\:\\ \ \(0\)\
\-\ ana\\ and\\ anti\\-dsdna\\ positive\ \(0\)\
\-\ all\\ other\\ causes\\ of\\ myelitis\\ were\\ ruled\\ out\\ by\\ clinical\\,\\ laboratory\\ \\(csf\\ analysis\\,\\ blood\\ tests\\)\\,\\ imaging\\ data\\ and\\ the\\ evolution\\ of\\ the\\ process\\.\\ the\\ patients\\ fulfilled\\ the\\ criteria\\ for\\ lupus\\ and\\ neuropsychiatric\\ lupus\\.\ \(0\)\
\-\ complete\\ neurological\\ recovery\\ and\\ normal\\ follow\\-up\\ mri\\ 5\\ months\\ later\\.\ \(0\)\
\-\ pattern\\ of\\ transverse\\ myelitis\\:\\ extensive\\ longitudinal\\ and\\ axial\\ involvement\\ of\\ cervical\\,\\ thoracic\\ and\\ bulbar\\ level\\.\ \(0\)\
\-\ no\\ supratentorial\\ lesions\\ were\\ present\\.\ \(0\)\
\-\ lupus\\ myelitis\\.\ \(0\)\
\-\ acute\\ disseminated\\ encephalomyelitis\ \(7\)\
\-\ neuromyelitis\\ optica\ \(2\)\
\-\ infections\ \(134\)\
\-\ transverse\\ myelitis\\ \\(due\\ to\\ other\\ connective\\ tissue\\ disorders\\,\\ paraneoplastic\\ syndromes\\,\\ or\\ vasculitis\\)\ \(0\)\
\-\ idiopathic\\ transverse\\ myelitis\ \(0\)\
\-\ spinal\\ cord\\ neoplasm\ \(1\)\
\-\ 27\\ y\\.o\\.\\ woman\\ with\\ sensory\\ and\\ motor\\ complaints\\ in\\ upper\\ and\\ lower\\ extremities\\.\\ \\ she\\ has\\ a\\ two\\ year\\.\\ history\\ of\\ lupus\\ erythematosus\ \(0\)\
\-\ myelopathy\\ is\\ one\\ of\\ the\\ most\\ debilitating\\ complications\\ of\\ npsle\\.\\ it\\ has\\ a\\ prevalence\\ of\\ 1\\-5\\%\\ of\\ the\\ sle\\ patients\\.\\ it\\ usually\\ develops\\ early\\ in\\ the\\ evolution\\ of\\ the\\ disease\\ leading\\ to\\ an\\ unfavorable\\ prognosis\\.\\ in\\ 39\\%\\ of\\ the\\ patients\\ with\\ lupus\\ related\\ myelopathy\\ it\\ constitutes\\ the\\ presenting\\ symptom\\ of\\ sle\\,\\ and\\ in\\ another\\ 42\\%\\ occurs\\ during\\ the\\ first\\ 5\\ years\\ after\\ the\\ diagnostic\\.\\ the\\ most\\ described\\ mri\\ pattern\\ in\\ sle\\ myelitis\\ is\\ consistent\\ with\\ transverse\\ myelitis\\:\\ commonly\\ long\\ affected\\ segment\\ \\(longitudinal\\ myelitis\\)\\ and\\ with\\ injury\\ of\\ both\\ halves\\ of\\ the\\ cord\\ on\\ axial\\ plane\\ \\(typically\\ almost\\ the\\ entire\\ transverse\\ area\\)\\.\\ transverse\\ myelitis\\ associates\\ a\\ variable\\ swelling\\ and\\ focal\\ enlargement\\.\\ enhancement\\ is\\ usually\\ absent\\ or\\ poor\\,\\ patchy\\.\\ the\\ pattern\\ of\\ transverse\\ myelitis\\ represents\\ an\\ abnormal\\ and\\ nonspecific\\ reaction\\ of\\ the\\ immune\\ system\\ against\\ the\\ spinal\\ cord\\.\\ it\\ is\\ the\\ result\\ of\\ different\\ inflammatory\\ disorders\\ of\\ the\\ spinal\\ cord\\,\\ it\\ could\\ be\\ apparently\\ idiopathic\\ or\\ associated\\ with\\ infections\\,\\ vaccination\\ \\(acute\\ disseminated\\ encephalomyelitis\\)\\,\\ neuromyelitis\\ optica\\,\\ connective\\ tissue\\ disorders\\,\\ paraneoplastic\\ syndrome\\ or\\ vasculitis\\.\\ even\\ spinal\\ cord\\ tumours\\ might\\ be\\ sometimes\\ difficult\\ to\\ distinguish\\ from\\ a\\ transverse\\ myelitis\\.\\ therefore\\ all\\ these\\ aetiologies\\ have\\ to\\ be\\ ruled\\ out\\ first\\ in\\ order\\ to\\ consider\\ sle\\ myelitis\\.\\ clinical\\ manifestations\\ of\\ myelitis\\ are\\ acute\\ or\\ subacute\\ onset\\ of\\ motor\\,\\ sensory\\ and\\ autonomic\\ dysfunction\\,\\ nonspecific\\,\\ which\\ obviously\\ has\\ an\\ important\\ overlap\\ with\\ other\\ inflammatory\\ entities\\.\\ the\\ outcome\\ of\\ sle\\ myelitis\\ is\\ variable\\,\\ ranging\\ from\\ complete\\ recovery\\ to\\ severe\\ disability\\,\\ but\\ the\\ injury\\ is\\ typically\\ much\\ less\\ extensive\\ or\\ absent\\ on\\ follow\\ up\\ mri\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ myelitis\\:\\ 0\\.634996914627379\ \(0\)\
\-\ transverse\\:\\ 0\\.23209785261285923\ \(0\)\
\-\ sle\\:\\ 0\\.19982744228014618\ \(0\)\
\-\ lupus\\:\\ 0\\.19619686693886743\ \(0\)\
\-\ the\\:\\ 0\\.16529545123280465\ \(0\)\
\-\ of\\:\\ 0\\.15474504321462196\ \(0\)\
\-\ cord\\:\\ 0\\.13955877993688473\ \(0\)\
\-\ spinal\\:\\ 0\\.10694863709008579\ \(0\)\
\-\ neuromyelitis\\:\\ 0\\.10593150221046833\ \(0\)\
\-\ optica\\:\\ 0\\.10593150221046833\ \(0\)\
\-\ and\\:\\ 0\\.10115083689345566\ \(0\)\
\-\ disorders\\:\\ 0\\.09973855207385059\ \(0\)\
\-\ it\\:\\ 0\\.0963739644888882\ \(0\)\
\-\ paraneoplastic\\:\\ 0\\.09298260941082007\ \(0\)\
\-\ myelopathy\\:\\ 0\\.09298260941082007\ \(0\)\
\-\ evolution\\:\\ 0\\.08819153663259933\ \(0\)\
\-\ encephalomyelitis\\:\\ 0\\.08819153663259933\ \(0\)\
\-\ pattern\\:\\ 0\\.08433768634081801\ \(0\)\
\-\ disseminated\\:\\ 0\\.0815629264684613\ \(0\)\
\-\ or\\:\\ 0\\.07859590141211585\ \(0\)\
\-\ connective\\:\\ 0\\.0782065312612018\ \(0\)\
\-\ ruled\\:\\ 0\\.07531458943175837\ \(0\)\
\-\ recovery\\:\\ 0\\.07407599566002944\ \(0\)\
\-\ variable\\:\\ 0\\.07312580261858101\ \(0\)\
\-\ longitudinal\\:\\ 0\\.07157083278295619\ \(0\)\
\-\ sensory\\:\\ 0\\.07093446937185188\ \(0\)\
\-\ nonspecific\\:\\ 0\\.07078005843375135\ \(0\)\
\-\ vasculitis\\:\\ 0\\.06988969967598509\ \(0\)\
\-\ infections\\:\\ 0\\.06649236804923372\ \(0\)\
\-\ idiopathic\\:\\ 0\\.06370266862592872\ \(0\)\
\-\ patients\\:\\ 0\\.06354808288982389\ \(0\)\
\-\ is\\:\\ 0\\.0618715817527288\ \(0\)\
\-\ absent\\:\\ 0\\.061783550893544766\ \(0\)\
\-\ acute\\:\\ 0\\.0611088732845236\ \(0\)\
\-\ fulfilled\\:\\ 0\\.060217682422870705\ \(0\)\
\-\ npsle\\:\\ 0\\.060217682422870705\ \(0\)\
\-\ motor\\:\\ 0\\.059904694304587565\ \(0\)\
\-\ other\\:\\ 0\\.05866370024228973\ \(0\)\
\-\ extensive\\:\\ 0\\.05802446315321481\ \(0\)\
\-\ mri\\:\\ 0\\.05798537939367353\ \(0\)\
\-\ halves\\:\\ 0\\.05754121034438773\ \(0\)\
\-\ associates\\:\\ 0\\.05754121034438773\ \(0\)\
\-\ aetiologies\\:\\ 0\\.05754121034438773\ \(0\)\
\-\ to\\:\\ 0\\.05648124947886103\ \(0\)\
\-\ in\\:\\ 0\\.056203248885902765\ \(0\)\
\-\ constitutes\\:\\ 0\\.05564222318371715\ \(0\)\
\-\ neuropsychiatric\\:\\ 0\\.05416925430762167\ \(0\)\
\-\ debilitating\\:\\ 0\\.05416925430762167\ \(0\)\
\-\ autonomic\\:\\ 0\\.05296575110523417\ \(0\)\
\-\ typically\\:\\ 0\\.05286768879738503\ \(0\)\
\-\ complete\\:\\ 0\\.05278887074412361\ \(0\)\
\-\ unfavorable\\:\\ 0\\.051948203646312585\ \(0\)\
\-\ has\\:\\ 0\\.0515983834916948\ \(0\)\
\-\ inflammatory\\:\\ 0\\.05092325164151229\ \(0\)\
\-\ first\\:\\ 0\\.050821305307064225\ \(0\)\
\-\ obviously\\:\\ 0\\.050289279026751184\ \(0\)\
\-\ overlap\\:\\ 0\\.04959379506846811\ \(0\)\
\-\ out\\:\\ 0\\.049501617080011225\ \(0\)\
\-\ injury\\:\\ 0\\.04910930066674805\ \(0\)\
\-\ bulbar\\:\\ 0\\.0489646533003103\ \(0\)\
\-\ vaccination\\:\\ 0\\.0489646533003103\ \(0\)\
\-\ tumours\\:\\ 0\\.0489646533003103\ \(0\)\
\-\ clinical\\:\\ 0\\.04772725602507939\ \(0\)\
\-\ usually\\:\\ 0\\.0474097581252533\ \(0\)\
\-\ be\\:\\ 0\\.045824729886478524\ \(0\)\
\-\ entities\\:\\ 0\\.04501833582931455\ \(0\)\
\-\ ranging\\:\\ 0\\.04501833582931455\ \(0\)\
\-\ all\\:\\ 0\\.04482960845571746\ \(0\)\
\-\ erythematosus\\:\\ 0\\.04469627232867604\ \(0\)\
\-\ with\\:\\ 0\\.04423928666887686\ \(0\)\
\-\ ana\\:\\ 0\\.04381483262692705\ \(0\)\
\-\ axial\\:\\ 0\\.04350114290983853\ \(0\)\
\-\ apparently\\:\\ 0\\.04328647132557126\ \(0\)\
\-\ an\\:\\ 0\\.04319681982268612\ \(0\)\
\-\ supratentorial\\:\\ 0\\.04279728516800547\ \(0\)\
\-\ immune\\:\\ 0\\.04191584546625647\ \(0\)\
\-\ disability\\:\\ 0\\.04151566280117499\ \(0\)\
\-\ prevalence\\:\\ 0\\.04113836054844407\ \(0\)\
\-\ distinguish\\:\\ 0\\.04078146323423065\ \(0\)\
\-\ develops\\:\\ 0\\.040609999247088274\ \(0\)\
\-\ follow\\:\\ 0\\.04059804981297963\ \(0\)\
\-\ outcome\\:\\ 0\\.04012081308952248\ \(0\)\
\-\ tissue\\:\\ 0\\.039505364276811276\ \(0\)\
\-\ most\\:\\ 0\\.03919304469710247\ \(0\)\
\-\ were\\:\\ 0\\.038819574442271285\ \(0\)\
\-\ syndromes\\:\\ 0\\.038711012086417695\ \(0\)\
\-\ manifestations\\:\\ 0\\.03858527509705643\ \(0\)\
\-\ might\\:\\ 0\\.038461888469961084\ \(0\)\
\-\ symptom\\:\\ 0\\.03834076594590769\ \(0\)\
\-\ against\\:\\ 0\\.03810499115574767\ \(0\)\
\-\ plane\\:\\ 0\\.03799018839508186\ \(0\)\
\-\ criteria\\:\\ 0\\.037340386227102916\ \(0\)\
\-\ up\\:\\ 0\\.03725248713474645\ \(0\)\
\-\ consider\\:\\ 0\\.03703799783001472\ \(0\)\
\-\ data\\:\\ 0\\.03694020356202143\ \(0\)\
\-\ patchy\\:\\ 0\\.036655224385628585\ \(0\)\
\-\ dysfunction\\:\\ 0\\.036562901309290505\ \(0\)\
\-\ tests\\:\\ 0\\.03603454000793472\ \(0\)\
\-\ sometimes\\:\\ 0\\.035238275582849615\ \(0\)\
\-\ subacute\\:\\ 0\\.035238275582849615\ \(0\)\
\-\ analysis\\:\\ 0\\.03501699254901313\ \(0\)\
\-\ order\\:\\ 0\\.0348028875417629\ \(0\)\
\-\ different\\:\\ 0\\.034460790665037204\ \(0\)\
\-\ entire\\:\\ 0\\.034263731483538444\ \(0\)\
\-\ almost\\:\\ 0\\.033825590160929384\ \(0\)\
\-\ represents\\:\\ 0\\.033646366689698344\ \(0\)\
\-\ leading\\:\\ 0\\.033471880961897064\ \(0\)\
\-\ 42\\:\\ 0\\.033471880961897064\ \(0\)\
\-\ therefore\\:\\ 0\\.03319094527252444\ \(0\)\
\-\ prognosis\\:\\ 0\\.03313616493859632\ \(0\)\
\-\ much\\:\\ 0\\.03261200140676458\ \(0\)\
\-\ reaction\\:\\ 0\\.03203344220301084\ \(0\)\
\-\ important\\:\\ 0\\.03189639245620353\ \(0\)\
\-\ poor\\:\\ 0\\.031762130356069146\ \(0\)\
\-\ even\\:\\ 0\\.03167411582074643\ \(0\)\
\-\ 39\\:\\ 0\\.03129195811185387\ \(0\)\
\-\ difficult\\:\\ 0\\.03125083030058797\ \(0\)\
\-\ segment\\:\\ 0\\.031088834628271153\ \(0\)\
\-\ complaints\\:\\ 0\\.031009303637846073\ \(0\)\
\-\ affected\\:\\ 0\\.03096989461121536\ \(0\)\
\-\ neurological\\:\\ 0\\.030930719467425368\ \(0\)\
\-\ another\\:\\ 0\\.030814569977722115\ \(0\)\
\-\ described\\:\\ 0\\.03055124761981735\ \(0\)\
\-\ 27\\:\\ 0\\.030514473194041457\ \(0\)\
\-\ from\\:\\ 0\\.029909511987427834\ \(0\)\
\-\ csf\\:\\ 0\\.029753307177875693\ \(0\)\
\-\ occurs\\:\\ 0\\.029688272244384882\ \(0\)\
\-\ presenting\\:\\ 0\\.029496925735119882\ \(0\)\
\-\ enlargement\\:\\ 0\\.028867783966962067\ \(0\)\
\-\ complications\\:\\ 0\\.028839269916774744\ \(0\)\
\-\ system\\:\\ 0\\.028726429692872046\ \(0\)\
\-\ diagnostic\\:\\ 0\\.028698518478542465\ \(0\)\
\-\ extremities\\:\\ 0\\.02861548603337089\ \(0\)\
\-\ related\\:\\ 0\\.02861548603337089\ \(0\)\
\-\ causes\\:\\ 0\\.028452490286458684\ \(0\)\
\-\ process\\:\\ 0\\.028241240503248003\ \(0\)\
\-\ result\\:\\ 0\\.0281894677487958\ \(0\)\
\-\ thoracic\\:\\ 0\\.028138097899239135\ \(0\)\
\-\ commonly\\:\\ 0\\.02786249462178435\ \(0\)\
\-\ could\\:\\ 0\\.027389102418632818\ \(0\)\
\-\ laboratory\\:\\ 0\\.027343578152994406\ \(0\)\
\-\ involvement\\:\\ 0\\.027253460816776563\ \(0\)\
\-\ early\\:\\ 0\\.027142517157275396\ \(0\)\
\-\ cervical\\:\\ 0\\.02696879680629149\ \(0\)\
\-\ later\\:\\ 0\\.026947399729682124\ \(0\)\
\-\ neoplasm\\:\\ 0\\.025704847789654595\ \(0\)\
\-\ less\\:\\ 0\\.025616950454249394\ \(0\)\
\-\ swelling\\:\\ 0\\.025343295004231835\ \(0\)\
\-\ long\\:\\ 0\\.0249687856402052\ \(0\)\
\-\ positive\\:\\ 0\\.024812356700167498\ \(0\)\
\-\ area\\:\\ 0\\.024393105194610527\ \(0\)\
\-\ onset\\:\\ 0\\.024179000187360303\ \(0\)\
\-\ during\\:\\ 0\\.023850252136931198\ \(0\)\
\-\ severe\\:\\ 0\\.023836903310634604\ \(0\)\
\-\ years\\:\\ 0\\.023081681457278538\ \(0\)\
\-\ level\\:\\ 0\\.022745473977896415\ \(0\)\
\-\ on\\:\\ 0\\.02274458781248021\ \(0\)\
\-\ syndrome\\:\\ 0\\.022700415834657237\ \(0\)\
\-\ abnormal\\:\\ 0\\.022622296670214256\ \(0\)\
\-\ focal\\:\\ 0\\.02252319734243931\ \(0\)\
\-\ she\\:\\ 0\\.02241480422785873\ \(0\)\
\-\ two\\:\\ 0\\.022361267905577742\ \(0\)\
\-\ months\\:\\ 0\\.021917943389328277\ \(0\)\
\-\ blood\\:\\ 0\\.021868274288510813\ \(0\)\
\-\ enhancement\\:\\ 0\\.021673252944531984\ \(0\)\
\-\ due\\:\\ 0\\.021644490405106957\ \(0\)\
\-\ lesions\\:\\ 0\\.021625384769904846\ \(0\)\
\-\ one\\:\\ 0\\.02155894719040589\ \(0\)\
\-\ these\\:\\ 0\\.02126346883433351\ \(0\)\
\-\ both\\:\\ 0\\.020997977594413467\ \(0\)\
\-\ consistent\\:\\ 0\\.020417113786628156\ \(0\)\
\-\ upper\\:\\ 0\\.02012196143446503\ \(0\)\
\-\ associated\\:\\ 0\\.019846725263956325\ \(0\)\
\-\ imaging\\:\\ 0\\.019788694188194178\ \(0\)\
\-\ woman\\:\\ 0\\.019610567018432744\ \(0\)\
\-\ present\\:\\ 0\\.0193217275256563\ \(0\)\
\-\ lower\\:\\ 0\\.019241471310845294\ \(0\)\
\-\ have\\:\\ 0\\.0188104692643467\ \(0\)\
\-\ but\\:\\ 0\\.018620190387348756\ \(0\)\
\-\ after\\:\\ 0\\.018266796869192962\ \(0\)\
\-\ which\\:\\ 0\\.0171218585966111\ \(0\)\
\-\ by\\:\\ 0\\.015990268501517003\ \(0\)\
\-\ disease\\:\\ 0\\.015806005537225415\ \(0\)\
\-\ normal\\:\\ 0\\.015374064423761158\ \(0\)\
\-\ history\\:\\ 0\\.014386184396145325\ \(0\)\
\-\ are\\:\\ 0\\.014288155881784795\ \(0\)\
\-\ no\\:\\ 0\\.012244802640430215\ \(0\)\
\-\ year\\:\\ 0\\.011604363890238237\ \(0\)\
\-\ for\\:\\ 0\\.011412778500201875\ \(0\)\
